Upadacitinib for the Treatment of Atopic Dermatitis

Morgan Petronelli, Associate Editor

Emma Guttman-Yassky, MD, sits down with Dermatology Times® to discuss recently published results of a phase 3 study evaluating upadacitinib (Rinvoq, AbbVie) as a potential treatment of atopic dermatitis.